Anebulo Pharmaceuticals, Inc. (ANEB) Income Statement
ANEB FY2025 at a glance
Fiscal year ended June 30, 2025 · U.S. dollarsANEB revenue and net income
ANEB growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ANEB quarterly EPS vs estimates
Anebulo Pharmaceuticals beat the analyst EPS estimate in 6 of the last 8 quarters.
ANEB income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $4.3M | $3.5M | $5.6M | $3.0M | $2.3M | $150,000 |
| Sales, general & admin | $4.9M | $4.8M | $6.2M | $3.9M | $1.3M | $140,106 |
| Total operating expenses | $9.2M | $8.3M | $11.8M | $6.8M | $3.6M | $173,351 |
| Operating income | −$9.2M | −$8.3M | −$11.8M | −$6.8M | −$3.6M | −$173,351 |
| Interest income | $257,913 | $249,022 | $147,605 | $92,407 | $7,332 | $1,290 |
| Interest expense | $382,014 | $151,230 | $0 | $7,332 | $11,767 | $1,286 |
| Income before taxes | −$8.5M | −$8.2M | −$11.7M | −$6.8M | −$30.3M | −$174,637 |
| Income taxes | — | — | −$104,191 | −$12,887 | $10,747 | −$1,040 |
| Net income | −$8.5M | −$8.2M | −$11.7M | −$6.8M | −$30.3M | −$174,637 |
| EBITDA | −$7.7M | −$7.9M | −$11.8M | −$6.8M | −$30.2M | −$173,351 |
| EPS (diluted) | −$0.26 | −$0.32 | −$0.47 | −$0.27 | −$1.01 | −$0.14 |
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $1.2M | $809,991 | $1.1M | $638,324 | $1.2M | $1.3M | $467,706 | $748,339 | $1.1M | $1.3M | $1.4M | $1.1M |
| Sales, general & admin | $1.5M | $1.5M | $1.2M | $1.3M | $1.4M | $1.1M | $872,661 | $915,912 | $1.7M | $1.3M | $1.1M | $1.8M |
| Total operating expenses | $2.6M | $2.3M | $2.3M | $1.9M | $2.6M | $2.4M | $1.3M | $1.7M | $2.8M | $2.5M | $2.5M | $2.9M |
| Operating income | −$2.6M | −$2.3M | −$2.3M | −$1.9M | −$2.6M | −$2.4M | −$1.3M | −$1.7M | −$2.8M | −$2.5M | −$2.5M | −$2.9M |
| Interest income | $85,410 | $109,616 | $122,583 | $102,257 | $7,067 | $26,006 | $50,218 | $68,084 | $75,522 | $55,198 | $6 | $79,152 |
| Interest expense | $17,439 | $17,439 | $17,439 | $245,182 | $59,696 | $59,697 | $59,696 | $59,696 | $31,838 | $0 | $52,452 | $66,070 |
| Income before taxes | −$2.0M | −$2.2M | −$2.1M | −$1.7M | −$2.5M | −$2.2M | −$1.3M | −$1.7M | −$2.7M | −$2.5M | −$2.5M | −$2.8M |
| Income taxes | — | — | — | — | −$2.5M | — | $9,478 | −$1.7M | −$2,760 | −$57,741 | $52,452 | −$66,070 |
| Net income | −$2.0M | −$2.2M | −$2.1M | −$1.7M | −$2.5M | −$2.2M | −$1.3M | −$1.7M | −$2.7M | −$2.5M | −$2.5M | −$2.8M |
| EBITDA | −$2.0M | −$2.1M | −$2.1M | −$1.2M | −$2.3M | −$2.1M | −$1.3M | −$1.6M | −$2.7M | $62,678 | −$2.5M | $66,041 |
| EPS (diluted) | −$0.05 | −$0.05 | −$0.05 | −$0.04 | −$0.09 | −$0.08 | −$0.05 | −$0.06 | −$0.11 | −$0.10 | −$0.10 | −$0.11 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ANEB's financial statements (latest annual report filed September 29, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ANEB financial results
Anebulo Pharmaceuticals reported no revenue in fiscal year 2025 (ended June 30, 2025). It had a net loss of $8.5 million. Diluted earnings per share came to −$0.26.
See the ANEB stock overview for the latest quote and news, or the ANEB chart for price history and technical indicators.
ANEB income statement FAQ
Does Anebulo Pharmaceuticals have revenue?
Anebulo Pharmaceuticals reported no revenue for fiscal year 2025, which ended on June 30, 2025.
Is Anebulo Pharmaceuticals profitable?
No. Anebulo Pharmaceuticals reported a net loss of $8.5 million in fiscal 2025.
How much does Anebulo Pharmaceuticals spend on research and development?
Anebulo Pharmaceuticals spent $4.3 million on research and development in fiscal 2025.
What are Anebulo Pharmaceuticals's earnings per share?
Anebulo Pharmaceuticals earned $-0.26 per diluted share in fiscal 2025, compared with $-0.32 a year earlier.
When does Anebulo Pharmaceuticals's fiscal year end?
Anebulo Pharmaceuticals's fiscal year ends in June. The latest annual report covers the year ended June 30, 2025 and was filed on September 29, 2025.